Saltar al contenido
Black Friday — 30% OFFEnvío gratis en pedidos desde 99 €
  1. Inicio
  2. Control del peso y metabolismo
  3. Orforglipron 6mg / 90caps
Control del peso

Orforglipron 6mg / 90caps

Orforglipron is a synthetic, non-peptidic GLP-1 receptor agonist studied in controlled research environments for its role in modulating glucagon-like peptide-1 signalling pathways.

Presentación: Orforglipron 6mg / 90caps.

Envase ilustrativo generado con IA.

El precio original era: 198,95 €.El precio actual es: 139,27 €.

Disponible bajo solicitud en España

Consulta a un asesor
Un asesor se pone en contacto contigo y la farmacia asociada comprueba si es posible continuar y cómo. Puede ser necesaria una receta válida o una evaluación a través de un servicio de telemedicina autorizado.
  • Farmacia asociada
  • Atención personalizada
  • Entrega discreta
  • Presentación
    Orforglipron 6mg / 90caps

Envío y entrega

  • Envío habitual en 24 horas tras confirmarse el pago.
  • USPS Regular Shipping · 11,95 € · Aprox. 3–5 días laborables
  • FedEx 2 Days Delivery · 28,99 € · Aprox. 2 días laborables
  • FedEx Overnight Delivery · 40,99 € · Aprox. 1 día laborable

Solo para investigación de laboratorio.

No apto para uso humano o veterinario.

Composición y detalles del producto

Descripción

Orforglipron is a synthetic, non-peptidic GLP-1 receptor agonist studied in controlled research environments for its role in modulating glucagon-like peptide-1 signalling pathways. Research focuses on its activity in cAMP-dependent pathways, receptor activation dynamics, and peptide-regulated energy balance mechanisms.

Unlike traditional GLP-1 analogues, Orforglipron demonstrates oral bioactivity and high receptor selectivity, making it suitable for experimental models evaluating small molecule agonists in metabolic signalling systems.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only
All SwissChems products are independently third-party tested at a USA-based HPLC-licensed laboratory prior to distribution. Certificates of Analysis (COA) are published on the Independent Test Results page and available at product level. If any independently conducted HPLC test returns a negative result, SwissChems will refund: (1) the cost of the HPLC test, and (2) the full order amount including shipping.

Propiedades

Chemical Formula C48H48F2N10O5
Synonyms LY3502970, OWL833, Foundayo (trade name)
Molar Mass 883.0 g/mol
CAS Number 2212020-52-3
PubChem CID 137319706
Total Compound Content 540 mg (6 mg per capsule)
Shelf Life 36 months

Investigación

Orforglipron (LY3502970) is a non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist developed as a first-in-class orally active GLP-1R modulator. Unlike peptide-based GLP-1R agonists that bind the receptor’s extracellular orthosteric peptide-binding domain, Orforglipron interacts with a distinct binding pocket within the transmembrane region of GLP-1R. This unique binding mechanism enables oral bioavailability while maintaining potent receptor activation. In cellular assays, Orforglipron activates Gs-coupled GLP-1R signalling, stimulating adenylate cyclase activity and increasing intracellular cAMP levels with an EC₅₀ of approximately 3 nM. Selectivity over related class B GPCRs, including the GIP receptor, glucagon receptor, and GLP-2 receptor, has been demonstrated in receptor-screening studies. Research applications include GLP-1 receptor pharmacology, allosteric receptor activation mechanisms, non-peptide GPCR agonist development, receptor conformational biology, ligand-binding studies, and comparative analysis of peptide versus small-molecule GLP-1R agonists. The extended elimination half-life of approximately 29–49 hours makes Orforglipron a useful tool for investigating sustained GLP-1R signalling and long-duration receptor activation. Supplied in 6 mg capsules. Independently third-party HPLC-tested; COA available per batch.

FAQ

How does Orforglipron’s binding mechanism differ from peptide GLP-1R agonists?

Peptide GLP-1R agonists interact primarily with the receptor’s extracellular peptide-binding domain, whereas Orforglipron binds within the transmembrane region of GLP-1R through a distinct small-molecule binding site. This alternative binding mode stabilizes an active receptor conformation through a mechanism different from endogenous peptide ligands.

As a result, Orforglipron is a valuable research tool for investigating allosteric receptor activation, receptor conformational dynamics, and the differences between peptide-mediated and small-molecule-mediated GLP-1R signalling.

What advantages does Orforglipron provide for GLP-1R pharmacology research?

As an orally active small-molecule agonist, Orforglipron enables investigation of GLP-1R activation without the structural constraints associated with peptide ligands. This makes it useful for studies examining receptor binding-site architecture, signal-transduction mechanisms, receptor trafficking, ligand-specific signalling profiles, and the development of non-peptide class B GPCR agonists.

Its distinct binding mode also allows direct comparison of orthosteric versus non-orthosteric receptor activation mechanisms.

Why is Orforglipron important for studying GLP-1 receptor signalling?

Orforglipron provides a unique platform for exploring how different ligand classes activate the same receptor. Comparative studies can evaluate receptor activation kinetics, cAMP signalling, receptor internalisation, signalling bias, and conformational changes induced by small-molecule versus peptide agonists. These investigations contribute to a broader understanding of GLP-1R pharmacology and class B GPCR activation mechanisms.

Los excipientes de la cápsula no se especifican en la documentación disponible.

El precio original era: 198,95 €.El precio actual es: 139,27 €.